From Yahoo Finance: 2025-04-01 12:52:00

Chimerix Inc. (CMRX) is a biopharmaceutical company with 17 hedge fund holders and an average upside potential of 131.01% as of March 31, 2025. The company’s R&D expenses increased in Q4 2024, with a focus on gaining FDA approval for Dordaviprone treatment for rare brain cancer. Dordaviprone has received key designations and is awaiting a decision by August 18, 2025, for potential commercial launch. CMRX ranks 1st on the list of best performing NASDAQ stocks in 2025, showing growth potential in the AI sector.

T. Rowe Price portfolio manager Tony Wang discussed tech sector volatility on CNBC, emphasizing the potential buying opportunity presented by the NASDAQ’s recent decline. Wang sees growth and momentum in tech stocks, anticipating improved valuations. He highlighted the importance of cost reduction and the potential for deep tech to expand market access, showing confidence in the sector’s prospects.

The Finviz stock screener compiled a list of the 11 best-performing NASDAQ stocks in 2025, ranked by year-to-date gains as of March 31. Hedge fund sentiment for each stock was included, sourced from Insider Monkey’s database. Research suggests that imitating top hedge fund stock picks can outperform the market, with a strategy that has returned 373.4% since May 2014, beating its benchmark by 218 percentage points.

Read more: Is Chimerix Inc. (CMRX) the Best Performing NASDAQ Stock So Far in 2025?